Read + Share
Foulkes DM, Fernig DG, McLean K, Held M, et al. Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas
aeruginosa ExoU and improves corneal infection outcomes. PLoS Pathog 2026;22:e1014474.
PMID: 42546044
|
 |
|
Foulkes DM, Fernig DG, McLean K, Held M, et al. Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas
aeruginosa ExoU and improves corneal infection outcomes. PLoS Pathog 2026;22:e1014474.
PMID: 42546044
|
|
|
|